http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 18:08:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+15++Filed+by%3A+Dickinson+Andrew+D/26780815.html si-local-file:///var/storage/secattach/20260716/26780815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+15++Filed+by%3A+Dickinson+Andrew+D/26780815.html Thu, 16 Jul 2026 18:08:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+15++Filed+by%3A+Dickinson+Andrew+D/26780815.html si-local-file:///var/storage/secattach/20260716/26780815.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+15++Filed+by%3A+Dickinson+Andrew+D/26780815.html Thu, 16 Jul 2026 18:08:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+15++Filed+by%3A+Mercier+Johanna/26780379.html si-local-file:///var/storage/secattach/20260716/26780379.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+15++Filed+by%3A+Mercier+Johanna/26780379.html Thu, 16 Jul 2026 16:55:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+15++Filed+by%3A+Mercier+Johanna/26780379.html si-local-file:///var/storage/secattach/20260716/26780379.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+15++Filed+by%3A+Mercier+Johanna/26780379.html Thu, 16 Jul 2026 16:55:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Mercier+Johanna/26774272.html si-local-file:///var/storage/secattach/20260715/26774272.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Mercier+Johanna/26774272.html Wed, 15 Jul 2026 16:13:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Mercier+Johanna/26774272.html si-local-file:///var/storage/secattach/20260715/26774272.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Mercier+Johanna/26774272.html Wed, 15 Jul 2026 16:13:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Dickinson+Andrew+D/26774240.html si-local-file:///var/storage/secattach/20260715/26774240.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Dickinson+Andrew+D/26774240.html Wed, 15 Jul 2026 16:11:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Dickinson+Andrew+D/26774240.html si-local-file:///var/storage/secattach/20260715/26774240.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++GILEAD+SCIENCES%2C+INC.++++++++++++++++++Filed+by%3A+Dickinson+Andrew+D/26774240.html Wed, 15 Jul 2026 16:11:00 -0400 GILD O.00092067 http://www.streetinsider.com/Analyst+PT+Change/Gilead+Sciences+%28GILD%29+PT+Lowered+to+%24166+at+Morgan+Stanley/26744660.html Morgan Stanley analyst Terence Flynn lowered the price target on Gilead Sciences (NASDAQ: GILD) to $166.00 (from $168.00) while maintaining a Overweight rating. http://www.streetinsider.com/Analyst+PT+Change/Gilead+Sciences+%28GILD%29+PT+Lowered+to+%24166+at+Morgan+Stanley/26744660.html Wed, 08 Jul 2026 08:08:22 -0400 GILD http://www.streetinsider.com/Analyst+PT+Change/Gilead+Sciences+%28GILD%29+PT+Lowered+to+%24120+at+RBC+Capital/26738627.html RBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) to $120.00 (from $122.00) while maintaining a Sector Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Gilead+Sciences+%28GILD%29+PT+Lowered+to+%24120+at+RBC+Capital/26738627.html Tue, 07 Jul 2026 07:55:18 -0400 GILD http://www.streetinsider.com/Analyst+PT+Change/Gilead+Sciences+%28GILD%29+PT+Lowered+to+%24156+at+Truist+Securities/26738276.html Truist Securities analyst Greg Renza lowered the price target on Gilead Sciences (NASDAQ: GILD) to $156.00 (from $157.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Gilead+Sciences+%28GILD%29+PT+Lowered+to+%24156+at+Truist+Securities/26738276.html Tue, 07 Jul 2026 07:09:09 -0400 GILD http://www.streetinsider.com/Analyst+PT+Change/HSBC+Upgrades+Gilead+Sciences+%28GILD%29+to+Buy/26731457.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar upgraded Gilead Sciences (NASDAQ: GILD) from Hold to Buy with a price target of $155.00 (from $133.00).</p><p>The analyst comments: “The market is too pessimistic on the HIV market post-dolutegravir generics, in our view. We believe the long-acting HIV therapies will improve adherence and help offset declines, supporting better-than-consensus HIV forecasts. Furthermore, short-term upside could come from high-growth PrEP (Yeztugo) and oncology catalysts (anito-cel, Trodelvy), with the recent share price correction and 13x next year earnings making valuation attractive.”</p><p>For an analyst ratings summary and ratings history on Gilead Sciences <a http://www.streetinsider.com/Analyst+PT+Change/HSBC+Upgrades+Gilead+Sciences+%28GILD%29+to+Buy/26731457.html Mon, 06 Jul 2026 05:41:23 -0400 GILD http://www.streetinsider.com/Upgrades/HSBC+Upgrades+Gilead+Sciences+%28GILD%29+to+Buy/26731457.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar upgraded Gilead Sciences (NASDAQ: GILD) from Hold to Buy with a price target of $155.00 (from $133.00).</p><p>The analyst comments: “The market is too pessimistic on the HIV market post-dolutegravir generics, in our view. We believe the long-acting HIV therapies will improve adherence and help offset declines, supporting better-than-consensus HIV forecasts. Furthermore, short-term upside could come from high-growth PrEP (Yeztugo) and oncology catalysts (anito-cel, Trodelvy), with the recent share price correction and 13x next year earnings making valuation attractive.”</p><p>For an analyst ratings summary and ratings history on Gilead Sciences <a http://www.streetinsider.com/Upgrades/HSBC+Upgrades+Gilead+Sciences+%28GILD%29+to+Buy/26731457.html Mon, 06 Jul 2026 05:41:23 -0400 GILD http://www.streetinsider.com/Analyst+Comments/HSBC+Upgrades+Gilead+Sciences+%28GILD%29+to+Buy/26731457.html (Updated - July 6, 2026 5:41 AM EDT) <p>HSBC analyst Rajesh Kumar upgraded Gilead Sciences (NASDAQ: GILD) from Hold to Buy with a price target of $155.00 (from $133.00).</p><p>The analyst comments: “The market is too pessimistic on the HIV market post-dolutegravir generics, in our view. We believe the long-acting HIV therapies will improve adherence and help offset declines, supporting better-than-consensus HIV forecasts. Furthermore, short-term upside could come from high-growth PrEP (Yeztugo) and oncology catalysts (anito-cel, Trodelvy), with the recent share price correction and 13x next year earnings making valuation attractive.”</p><p>For an analyst ratings summary and ratings history on Gilead Sciences <a http://www.streetinsider.com/Analyst+Comments/HSBC+Upgrades+Gilead+Sciences+%28GILD%29+to+Buy/26731457.html Mon, 06 Jul 2026 05:41:23 -0400 GILD http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+01++Filed+by%3A+O%26apos%3BDay+Daniel+Patrick/26727907.html si-local-file:///var/storage/secattach/20260702/26727907.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+01++Filed+by%3A+O%26apos%3BDay+Daniel+Patrick/26727907.html Thu, 02 Jul 2026 16:14:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+01++Filed+by%3A+O%26apos%3BDay+Daniel+Patrick/26727907.html si-local-file:///var/storage/secattach/20260702/26727907.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Jul+01++Filed+by%3A+O%26apos%3BDay+Daniel+Patrick/26727907.html Thu, 02 Jul 2026 16:14:00 -0400 GILD O.00092067 http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).</p> <p>Trodelvy is now approved as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex for patients whose tumors express PD-L1 with a combined positive score of 10 or higher, as determined by an FDA-authorized test.</p> <p>The approval is based on data from two Phase 3 trials. In the ASCENT-03 trial, Trodelvy as monotherapy reduced the http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html Wed, 24 Jun 2026 16:29:20 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).</p> <p>Trodelvy is now approved as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex for patients whose tumors express PD-L1 with a combined positive score of 10 or higher, as determined by an FDA-authorized test.</p> <p>The approval is based on data from two Phase 3 trials. In the ASCENT-03 trial, Trodelvy as monotherapy reduced the http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html Wed, 24 Jun 2026 16:29:20 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).</p> <p>Trodelvy is now approved as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex for patients whose tumors express PD-L1 with a combined positive score of 10 or higher, as determined by an FDA-authorized test.</p> <p>The approval is based on data from two Phase 3 trials. In the ASCENT-03 trial, Trodelvy as monotherapy reduced the http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html Wed, 24 Jun 2026 16:29:20 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).</p> <p>Trodelvy is now approved as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex for patients whose tumors express PD-L1 with a combined positive score of 10 or higher, as determined by an FDA-authorized test.</p> <p>The approval is based on data from two Phase 3 trials. In the ASCENT-03 trial, Trodelvy as monotherapy reduced the http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html Wed, 24 Jun 2026 16:29:20 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).</p> <p>Trodelvy is now approved as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex for patients whose tumors express PD-L1 with a combined positive score of 10 or higher, as determined by an FDA-authorized test.</p> <p>The approval is based on data from two Phase 3 trials. In the ASCENT-03 trial, Trodelvy as monotherapy reduced the http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html Wed, 24 Jun 2026 16:29:20 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).</p> <p>Trodelvy is now approved as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex for patients whose tumors express PD-L1 with a combined positive score of 10 or higher, as determined by an FDA-authorized test.</p> <p>The approval is based on data from two Phase 3 trials. In the ASCENT-03 trial, Trodelvy as monotherapy reduced the http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html Wed, 24 Jun 2026 16:29:20 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).</p> <p>Trodelvy is now approved as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex for patients whose tumors express PD-L1 with a combined positive score of 10 or higher, as determined by an FDA-authorized test.</p> <p>The approval is based on data from two Phase 3 trials. In the ASCENT-03 trial, Trodelvy as monotherapy reduced the http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html Wed, 24 Jun 2026 16:29:20 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344 http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Trodelvy (sacituzumab govitecan-hziy) for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC).</p> <p>Trodelvy is now approved as a single agent for patients who are not candidates for PD-(L)1 inhibitor-based therapy, and in combination with Keytruda (pembrolizumab) or Keytruda Qlex for patients whose tumors express PD-L1 with a combined positive score of 10 or higher, as determined by an FDA-authorized test.</p> <p>The approval is based on data from two Phase 3 trials. In the ASCENT-03 trial, Trodelvy as monotherapy reduced the http://www.streetinsider.com/FDA/FDA+clears+Gilead%27s+Trodelvy+for+first-line+metastatic+TNBC/26685900.html Wed, 24 Jun 2026 16:29:20 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Trodelvy%C2%AE+for+First-Line+Treatment+of+Metastatic+Triple-Negative+Breast+Cancer/26685894.html <p class="bwalignc"> <i>– <b>Trodelvy is a</b></i><b><i> New Backbone Therapy and the Only Approved ADC in First-Line mTNBC Across PD-L1 Status –</i></b> </p><p class="bwalignc"> <b><i>– Approval Builds on Trodelvy’s Leadership in Second-Line mTNBC and Pre-Treated HR+/HER2- Metastatic Breast Cancer with More than 75,000 Patients Treated Globally –</i></b> </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Trodelvy%C2%AE+for+First-Line+Treatment+of+Metastatic+Triple-Negative+Breast+Cancer/26685894.html Wed, 24 Jun 2026 16:29:00 -0400 A.06822034 A.20922990 A.37819586 GILD O.00000304 O.00048977 O.00092067 O.20026344